Reshape Lifesciences (NASDAQ:HIND) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Reshape Lifesciences (NASDAQ:HIND) from a sell rating to a hold rating in a research report released on Tuesday.

Reshape Lifesciences Stock Down 2.8%

Shares of HIND opened at $5.63 on Tuesday. Reshape Lifesciences has a 12 month low of $5.60 and a 12 month high of $749.00. The firm has a market cap of $3.79 million, a P/E ratio of -0.01 and a beta of 1.02.

About Reshape Lifesciences

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.